The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s demonstrating significant promise in clinical trials for treating obesity. Unlike some existing weight loss solutions, retatrutide appears to deliver a greater substantial loss in body weight and improve metabolic markers, pa… Read More